The Phase I/II Extension and the Phase I/III Clinical trial into Roche RO7239361 has been terminated, on the basis of interim data.

Duchenne UK announces funding of £193,487 for two new DMD Hub posts at Evelina Children’s Hospital in London, to help more patients with DMD in London and the South access clinical trials.

This will significantly expand trial capacity for Duchenne Muscular Dystrophy in the UK, particularly in the north west of England.

The charity's co-founder Alex Johnson -- recently awarded the Pride of Manchester -- said it was a huge boost to research in the region.

We are pleased to announce that Catabasis Pharmaceutical's PolarisDMD Phase 3 trial for edasalonexent is now recruiting in the UK at Bristol Royal Hospital for Children. Evelina London Children's Hospital, Great Ormond Street Hospital and Royal Manchester Children’s Hospital will begin recruitment soon.

We are pleased to announce that the VISION-DMD Phase 2b clinical trial has begun recruitment at Newcastle upon Tyne NHS Hospital Foundation Trust and Royal Hospital for Children, Glasgow.

This article was originally published on Muscular Dystrophy News.

Bristol Royal Hospital for Children joins the DMD Hub as a Hub site.